jump to navigation

NIH/SBIR Grant Awarded to Firm Client BioAxone BioSciences for BA-1049 Inhibitor Research 08/03/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

The National Institutes of Health (NIH), Small Business Innovation Research (SBIR), and National Institute of Neurological Disorders and Stroke have awarded firm client BioAxone BioSciences, Inc. with a $1.5 million grant. The grant is for continued research for BioAxone’s Rho Kinase 2 (ROCK2) inhibitor, BA-1049, a transformative drug to treat cerebral cavernous malformation, a serious genetic disease.

BioAxone is a clinical-state biopharmaceutical company developing regenerative therapeutic drugs based on a deep understanding of axon regeneration and neuronal signaling pathways.

Congratulations to our client on receiving the grant and on their revolutionary drug research. For more information, read the full release.

Blue Stream Laboratories Acquired by Charles River Laboratories 06/28/2016

Posted by Morse Barnes-Brown Pendleton in Client News, Deal News, Life Sciences, MBBP news.
Tags: , , , , , , , , ,
add a comment

blue streamMBBP client Blue Stream Laboratories, an analytical contract research organization supporting the development of complex biologics and biosimilars, was acquired by Charles River Laboratories. Charles River Laboratories is a provider of essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

According to Blue Stream, “The synergy of combining Blue Stream’s core expertise with Charles River’s existing broad portfolio of biopharmaceutical clinical development and supporting services creates a well-established services entity which can fully support biologic and biosimilar development.”

Morse, Barnes-Brown & Pendleton served as counsel to Blue Stream Laboratories and advised them in connection with the structuring, negotiation and documentation of this transaction. Shannon Zollo was the lead corporate attorney on MBBP’s team.

For more information, read the full news release.

%d bloggers like this: